Mass-producing RPE cells paves way to treating AMD

Article

New treatments for age-related macular degeneration may be on the horizon because researchers are now able to develop pluripotent stem cells faster and easier.

Durham, NC-Scientists have developed a new, simpler way to produce human pluripotent stem cells in quantities large enough that they can be used to develop treatments for age-related macular degeneration (AMD). The results of this new study are published in the May issue of Stem Cells Translational Medicine

“As a result, there has been significant interest in developing retinal pigment epithelial (RPE) culture systems both to study AMD disease mechanisms and to provide substrate for possible cell-based therapies,” said Donald Zack, MD, PhD, who with Julien Maruotti, PhD, led the team of researchers from the Wilmer Institute, Johns Hopkins University School of Medicine, Baltimore, and the Institute of Vision in Paris in conducting the study.

The Zack/Maruotti team simplified RPE cell production by modifying a standard protocol for isolating the cells from spontaneously differentiating human pluripotent stem cell (hPSC) monolayers. In the new method, hPSCs were amplified by clonal propagation and the RPE cells enriched by serial passage rather than mechanical picking.

“These modifications eliminate the need for the time- and labor-consuming manual steps usually required to culture hPSCs and to purify the RPE population, and thereby provide a readily scalable approach to generate large numbers of high quality RPE cells-up to 36 times more than the best protocols previously reported during the same time interval,” Dr. Zack said.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Patricia Buehler, MD, MPH, at ASCRS 2025
Brett Bielory, MD, at ASCRS 2025
At ASCRS 2025, Alex Hacopian, MD, shares information from his presentation on next-gen presbyopia-correcting intraocular lenses.
Rhue and Canto-Sims talk the value of contact lens patients, financial insights, and key benefits of implementing a contact lens management system.
Eva Kim, MD, shares visual outcomes of EVO implantable collamer lens in patients with low to moderate myopia.
Drs Brianna Rhue and Diana Canto-Sims discuss the benefits of implementing a contact lens management system that can help improve lens sales at your practice.
Dr Ashley Wallace Tucker speaks on the Myopia Management Navigator.
Matt Jones, OD; Matt Burns; and Joe Sugg, OD; detailed what optometrists can expect to change when HB 1353's regulations are enacted later this year.
Arkansas Optometric Association legislative cochairs Matt Jones, OD; Matt Burns, OD; and Joe Sugg, OD, discuss their involvement in their bill and provide context for its relevance.
© 2025 MJH Life Sciences

All rights reserved.